BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a phase 2 clinical study, according to a press release from Boehringer Ingelheim.
The oral nature of BI 1815368 could change the paradigm for a disease currently treated with eye injections by retina specialists, according to Boehringer Ingelheim.
“DME is a highly bilateral condition, with about half of patients eventually developing the disease in the fellow eye. This poses a challenge in the management of the disease, as current treatments are (Read more...)